The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 17th Dec 2020 13:13

(Sharecast News) - Yellow Cake: Berenberg reiterates buy with a target price of 300p.



SSP: Berenberg reiterates hold with a target price of 335p.

Bunzl: Deutsche Bank reiterates buy with a target price of 2,971p.

Abcam: Peel Hunt reiterates hold with a target price of 1,530p.

AstraZeneca: Liberum reiterates buy with a target price of 9,430p.

Babcock: Liberum reiterates buy with a target price of 400p.

Electrocomponents: Barclays reiterates equal weight with a target price of 775p.

Dixons Carphone: Barclays reiterates overweight with a target price of 145p.

Fresnillo: RBC Capital Markets reiterates sector perform with a target price of 1,100p.

Polymetal International: RBC Capital Markets reiterates outperform with a target price 2,450p.

Related Shares

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negoti...

29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while a...

29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe a...

29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', ...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.